Author

M. Pizzi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:cell type annotation· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Assay:proteomics· 2 Research Focus:clustering· 1

Frequent Co-Authors

A. Rasola· 2 shared F. Ciscato· 2 shared I. Masgras· 2 shared A. Castegna· 1 shared A. Cavalli· 1 shared A. D. Cabras· 1 shared A. di Napoli· 1 shared A. Gori· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Rasola

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

P. Sindaco, S. Lonardi, G. Varano, I. Pietrini, G. Morello, P. Balzarini, H. Neuman, F. Vit, G. Bertolazzi, H. Arima, M. Chiarini, L. Lorenzi, V. Pellegrini, S. Giampaolo, D. Garzon, , S. Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

bioRxiv · Jul 13, 2024Cancer Biology

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

F. Spriano, L. Cascione, J. Sgrignani, N. Bendik, S. Napoli, G. Sartori, E. Cannas, T. Gong, A. J. Arribas, M. Pizzi, D. Rossi, D. F. Robbiani, A. Cavalli, F. Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD+ and SIRT3

I. Masgras, G. Cannino, F. Ciscato, C. Sanchez-Martin, M. Pizzi, A. Menga, A. Castegna, A. Rasola

This study shows that neurofibromin loss reduces mitochondrial respiration and NAD+ levels, promoting tumor growth, and that restoring NAD+ or SIRT3 can counteract this effect.

bioRxiv · May 29, 2021Cancer Biology

Evaluation of bacterial proliferation with a microfluidic-based device: Antibiochip.

M. Pizzi, V. Gallo, A. Ruiba, M. Zanin, P. Begnamino, S. Ledda, T. Pesce, G. Melioli

The paper evaluates the Antibiochip's ability to measure E. coli proliferation and antibiotic susceptibility, showing good linearity and rapid results.

bioRxiv · Oct 3, 2019Microbiology

Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca2+-dependent death of cancer cells

A. Rasola, F. Ciscato, R. Filadi, I. Masgras, M. Pizzi, O. Marin, N. Damiano, P. Pizzo, A. Gori, F. Frezzato, L. Trentin, P. Bernardi

The paper shows that displacing HK2 from MAMs triggers Ca2+-dependent death of cancer cells, offering a potential anti-neoplastic strategy.

bioRxiv · Aug 15, 2019Cancer Biology